Advances in disease-modifying therapy for multiple sclerosis

Abstract:

Disease-modifying therapy（DMT） is the standard therapy for reducing recurrence and improving prognosis during the remission stage of multiple sclerosis（MS）. A variety of DMT drugs with different action targets and mechanisms have been approved and marketed in China. With a deeper understanding of the pathophysiology of MS and the improvement of the treatment goals for MS，clinical trials are being conducted for several novel drugs to pursue better efficacy and safety. This article introduces the mechanism of action and clinical trial results of the DMT drugs approved in China and reviews the current research status of several new DMT drugs.